Response Genetics (RGDX.Q) Stock Analysis & Winston Score

Response Genetics was a small medical diagnostics company that analyzed tumor samples from cancer patients. It developed tests to help doctors figure out which chemotherapy drugs were most likely to work for a specific patient, based on the genetic makeup of their tumor. The company sold these tests mainly to oncologists and hospitals in the United States. The company made money by charging for each diagnostic test it performed on patient samples. It operated primarily in the U.S. and remained a small, niche player in the molecular diagnostics space, competing against larger lab companies with far greater resources. The ticker suffix ".Q" indicates the company went through bankruptcy, which reflects the core risk it faced: it struggled to achieve the scale needed to cover its costs, and it was never able to generate enough revenue to sustain operations against better-funded competitors in the personalized medicine market.